Panacea Life Sciences Holdings Q3 FY22: revenue $366K, down 38%; diluted EPS −$0.18

Key figures from this report

These are the numbers Panacea Life Sciences Holdings reported for Q3 FY22, the quarter ended Sep 30, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$366K−38% from $588K in Q3 FY2110-Q income statement, on EDGAR
2. Net income−$2.7MAgainst −$3.1M in Q3 FY2110-Q income statement, on EDGAR
3. Diluted EPS−$0.18Against −$0.14 in Q3 FY2110-Q income statement, on EDGAR
4. Cash and cash equivalents$37K+154% from $15K in Q3 FY21Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations−$711KAgainst −$753K in Q3 FY2110-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables